Loading
MDxHealth SA Stock: price and insider trades · United States
US·Mcap US$19.7M
1 insider bought €867k of shares over the last 90 days, the latest by MVM Partners, LLC, filed 17 Aug 2026.
MDxHealth SA: what insiders have been doing
MDxHealth SA is a listed company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 2 filings signed by 2 insiders.
The flow runs one way only: 1 insider bought (1 purchase totalling €867k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €867k, the purchase published on 17 August 2026 by MVM Partners, LLC is the largest of the period (1.8% of market cap). Those buying include 1 senior executive.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 2 filings, this issuer sits below that mark. Our records for MDxHealth SA go back to 2023, with 2 purchases and no sales on the open market in total. On the fundamentals side, the SEC filing (20-F) for the period ending 31 December 2025 lists revenue at 107.9 m USD and net income at -33.5 m USD.
The clock since the last published purchase (17 August 2026) now reads 68 days.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
3
Thresholds
n/a
Buy Volume
€5M
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleMVM Partners, LLC1 buy
Since the insiders bought
- -10.5%Entry US$0.75 · Close at T+30 US$0.67
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate MDxHealth SA Buy (bullish), based on 4 analysts. Average price target: US$1.13.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,732 of 26,284 companies
25.2
score / 100
Value6
Quality45
FCF yld-19%
Earn yld-192%
EV/EBITDA·
ROE·
Gross mgn65%
Net mgn-31%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.21
Analyst consensus
4 analystsBuy
US$0.50Target US$1.13(+445%)US$2.00
Income statement
RevenueUS$107.9M
Gross profitUS$69.6M65% margin
EBITDA-US$14.6M-13% margin
Net income-US$33.5M-32.7% margin
Valuation
PER (forward)-0.5x
Beta-518287.38
Balance sheet & cash
Market capUS$19.7M
Total debtUS$86.6M
Free Cash Flow-US$3.3M
Profitability & ownership
ROA-9.8%
% insiders22.1%
% institutions44.0%
Last declaration on 17 September 2026
Declarations3 total
1,500,000 shares@ US$0.70461.89% mcap100.0% of flowCommon StockSEC144:0001178937-26-000045
2,202,643 shares@ US$0.4541.78% mcap19.1% of flowOrdinary SharesSEC:0001193125-26-354021:0
Canonical exit: 11 Nov 2026 (T+90)
1,000,000 shares@ US$4.0080.9% of flowCommon StockSEC:0001062993-23-005104:0
Canonical exit: 4 May 2023 (T+90)
3 of 3 declarations
About MDxHealth SA
MDxHealth SA is a company focused on developing diagnostic tests for cancer, emphasizing personalized medicine. It is listed on NASDAQ.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
